Entera Bio welcomes Ron Mayron to its Board of Directors

– ISRAEL, Jerusalem / USA, MA –  Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Ron Mayron to its Board of Directors, replacing Zeev Bronfeld, a Founder of Entera, who served on its Board since 2010 and was Chairman from 2014 to 2016.

“We welcome Ron to the Board as we advance our pipeline of oral drug candidates for biologics and active ingredients that were previously only administrated through injection. Ron’s deep knowledge in the management and logistics of commercialized pharma products at Teva, as well as his vast experience serving on the boards of over a dozen private and publicly traded healthcare companies are assets to Entera.” said Board Chairman, Jerry Lieberman.

He added: “On behalf of the entire Board, I extend gratitude to Zeev for his insight as a Founder of Entera, his leadership as a Board member, and his twelve years of service to the Company. His contributions have helped Entera become a NASDAQ listed company and a global leader in the oral delivery of proteins. We wish him well.”

About Ron Mayron

Ron Mayron is a global healthcare specialist who serves on the boards of numerous public and privately held pharma and medical device companies in Israel, including DNA BioMedical Solutions, Innocan Pharma, and IceCure Medical. His prior executive experience includes several leadership positions culminating in CEO of Teva Israel & Africa and CEO of S.L.E. His expertise within healthcare includes M&A, integration and implementation, global business development, global operations, and supply chain management.

He earned a B.Sc. from Ben-Gurion University, an MBA from the University of Tel Aviv, and attended several programs at INSEAD University Fontainebleu, France, and the MIT, Boston. Mr. Mayron served as an Officer in the Israeli army achieving the rank of Major.

About Entera Bio

Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience, and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.

For more information, visit www.enterabio.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team